– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer –
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
Seeking Alpha / 8 hours ago 2 Views
Seeking Alpha / 8 hours ago 2 Views
– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer –
Comments